https://www.pharmaradar360.com/article/podcast-key-readouts-from-esc-and-ers-37928ee094726d75PharmaRadar360en2026-09-10T11:00:34.000ZPodcast: key readouts from ESC and ERShttps://www.pharmaradar360.com/article/hhs-appoints-permanent-fda-cber-cder-heads-40d9e998d4d06de3PharmaRadar360en2026-09-10T10:52:30.000ZHHS appoints permanent FDA CBER, CDER headshttps://www.pharmaradar360.com/article/spain-pushes-for-access-toolbox-in-eu-biotech-rules-1688a317e36915f9PharmaRadar360en2026-09-10T10:48:05.000ZSpain pushes for ‘access toolbox’ in EU biotech ruleshttps://www.pharmaradar360.com/article/join-the-danish-medicines-agency-s-atmp-open-house-c8681c32f51f75b3PharmaRadar360en2026-09-10T10:39:00.000ZJoin the Danish Medicines Agency’s ATMP Open Househttps://www.pharmaradar360.com/article/roivant-is-one-of-the-savviest-dealmakers-in-biotech-it-also-has-a-secret-weapon-c406bfe29c9a43b3PharmaRadar360en2026-09-10T10:31:42.000ZRoivant is one of the savviest dealmakers in biotech. It also has a secret weaponhttps://www.pharmaradar360.com/article/what-to-expect-from-uniqure-s-upcoming-huntington-s-gene-therapy-readout-e0aa083eeef3c734PharmaRadar360en2026-09-10T10:31:41.000ZWhat to expect from UniQure’s upcoming Huntington’s gene therapy readouthttps://www.pharmaradar360.com/article/squarepoint-ops-llc-sells-106-171-shares-of-ultragenyx-pharmaceutical-inc-rare-aaef604b00280d03PharmaRadar360en2026-09-10T10:16:39.000ZSquarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RAREhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-prices-4-9-billion-senior-notes-offering-and-anno-b1e8ff5e4e7ab9dfPharmaRadar360en2026-09-10T10:11:00.000ZTeva Pharmaceutical Industries Prices $4.9 Billion Senior Notes Offering and Announces Conditional Redemptionshttps://www.pharmaradar360.com/article/power-optimization-solution-ends-costly-grid-related-shutdowns-at-major-pharmace-895389c9339efb13PharmaRadar360en2026-09-10T10:00:00.000ZPower Optimization Solution Ends Costly Grid-Related Shutdowns at Major Pharmaceutical Manufacturing Planthttps://www.pharmaradar360.com/article/active-pharmaceutical-ingredients-market-demand-insights-ee7be79d74ee8b32PharmaRadar360en2026-09-10T09:46:00.000ZActive Pharmaceutical Ingredients Market Demand Insightshttps://www.pharmaradar360.com/article/one-assessment-27-countries-how-eu-joint-reviews-work-afdce1a4bab2fa1aPharmaRadar360en2026-09-10T09:44:09.000ZOne assessment, 27 countries: how EU joint reviews workhttps://www.pharmaradar360.com/article/takeda-pharmaceutical-co-ltd-takeda-announces-planned-retirement-of-president-of-cc51e8d4bc8214ffPharmaRadar360en2026-09-10T09:34:28.000ZTakeda Pharmaceutical Co Ltd - Takeda Announces Planned Retirement Of President Of Research & Development Andy Plump Effective June 2027https://www.pharmaradar360.com/article/takeda-pharmaceutical-announces-planned-retirement-of-president-of-research-deve-57aa87713cda8888PharmaRadar360en2026-09-10T09:34:06.000ZTakeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plumphttps://www.pharmaradar360.com/article/systech-launches-traceiq-0628e750134c6813PharmaRadar360en2026-09-10T09:33:40.000ZSystech launches TraceIQhttps://www.pharmaradar360.com/article/how-ud-s-star-campus-is-helping-companies-foster-innovation-in-biotech-bac768bf1af40fd7PharmaRadar360en2026-09-10T09:31:00.000ZHow UD's STAR Campus is helping companies foster innovation in biotechhttps://www.pharmaradar360.com/article/biotech-growth-trust-stands-out-in-a-stronger-biotechnology-sector-0c5fc1ee6f1de77bPharmaRadar360en2026-09-10T09:24:00.000ZBiotech Growth Trust Stands Out In A Stronger Biotechnology Sectorhttps://www.pharmaradar360.com/article/me-therapeutics-stock-faces-downside-pressure-as-biotech-risk-and-preclinical-un-1ec2178796d0ffa0PharmaRadar360en2026-09-10T09:19:00.000ZME Therapeutics Stock Faces Downside Pressure as Biotech Risk and Preclinical Uncertainty Weigh on Sentimenthttps://www.pharmaradar360.com/article/biocorrx-inc-appoints-former-acting-white-house-drug-policy-director-richard-j-b-f65963320838259aPharmaRadar360en2026-09-10T09:16:00.000ZBioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Boardhttps://www.pharmaradar360.com/article/when-the-er-is-not-an-option-milestone-s-cmo-on-bringing-afib-rate-control-home-e2e99f9bbe1ee809PharmaRadar360en2026-09-10T09:11:37.000ZWhen the ER Is Not an Option: Milestone’s CMO on Bringing AFib Rate Control Homehttps://www.pharmaradar360.com/article/yourgene-insight-dpyd-assay-gets-ivdr-accreditation-0f45b3e7e51c89f2PharmaRadar360en2026-09-10T09:10:10.000ZYourgene Insight DPYD assay gets IVDR accreditationhttps://www.pharmaradar360.com/article/latest-figures-highlight-ongoing-meningitis-b-risk-for-students-d7de382570d1ec44PharmaRadar360en2026-09-10T09:00:05.000ZLatest figures highlight ongoing Meningitis B risk for studentshttps://www.pharmaradar360.com/article/mog-fda-35ed387f5c4715cePharmaRadar360en2026-09-10T09:00:00.000Zエンスプリングに関するロシュ社の発表について（MOG抗体関連疾患に対するFDAによる申請受理および優先審査指定）https://www.pharmaradar360.com/article/roche-announces-u-s-fda-grants-priority-review-for-enspryng-for-myelin-oligodend-399e802924ad2be2PharmaRadar360en2026-09-10T09:00:00.000ZRoche Announces U.S. FDA Grants Priority Review for Enspryng for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)https://www.pharmaradar360.com/article/samsung-biologics-signs-350-8-billion-long-term-cmo-deal-with-european-pharmaceu-f69633ea36eaf3adPharmaRadar360en2026-09-10T08:55:00.000ZSamsung Biologics Signs ₩350.8 Billion Long-Term CMO Deal with European Pharmaceutical Companyhttps://www.pharmaradar360.com/article/biotech-fluidics-launch-degasi-ng-platform-03359e408ef2f244PharmaRadar360en2026-09-10T08:47:40.000ZBiotech Fluidics launch DEGASi NG platformhttps://www.pharmaradar360.com/article/dong-a-socio-holdings-to-rename-itself-dong-a-pharmaceutical-after-otc-merger-811dc3505dca9b48PharmaRadar360en2026-09-10T08:46:07.000ZDong-A Socio Holdings to rename itself Dong-A Pharmaceutical after OTC mergerhttps://www.pharmaradar360.com/article/biotech-fluidics-upgrades-its-degasi-inline-degasser-range-2e8eb202eff2dd75PharmaRadar360en2026-09-10T08:35:23.000ZBiotech Fluidics upgrades its Degasi inline degasser rangehttps://www.pharmaradar360.com/article/why-evidence-matters-seema-meloni-on-making-data-meaningful-ec1cdcab294170daPharmaRadar360en2026-09-10T08:33:17.000ZWhy evidence matters: Seema Meloni on making data meaningfulhttps://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323PharmaRadar360en2026-09-10T08:30:10.000ZSalmonella outbreak updatehttps://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884PharmaRadar360en2026-09-10T08:30:07.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007PharmaRadar360en2026-09-10T08:30:05.000ZSalmonella statistical releaseshttps://www.pharmaradar360.com/article/meningococcal-disease-laboratory-confirmed-cases-in-england-2025-to-2026-26816bdfcbfa7f60PharmaRadar360en2026-09-10T08:30:04.000ZMeningococcal disease: laboratory-confirmed cases in England 2025 to 2026https://www.pharmaradar360.com/article/antimicrobial-resistance-awareness-toolkit-for-healthcare-providers-0c0f57c6f41d20cePharmaRadar360en2026-09-10T08:30:03.000ZAntimicrobial resistance awareness: toolkit for healthcare providershttps://www.pharmaradar360.com/article/venture-investor-danish-biotech-has-caught-up-with-sweden-3b75feb145abd779PharmaRadar360en2026-09-10T08:20:45.000ZVenture investor: Danish biotech has caught up with Swedenhttps://www.pharmaradar360.com/article/pharmaceutical-packaging-market-c2e9bc2e819d9a7bPharmaRadar360en2026-09-10T08:16:48.000ZPharmaceutical Packaging Markethttps://www.pharmaradar360.com/article/ebola-disease-caused-by-bundibugyo-virus-democratic-republic-of-the-congo-22eadb56d9fb8544PharmaRadar360en2026-09-10T08:16:08.000ZEbola disease caused by Bundibugyo virus - Democratic Republic of the Congohttps://www.pharmaradar360.com/article/gov-healey-eyes-changes-to-life-sciences-programs-as-early-stage-biotechs-strugg-17782bbe9a7546e8PharmaRadar360en2026-09-10T08:00:00.000ZGov. Healey eyes changes to life sciences programs as early-stage biotechs strugglehttps://www.pharmaradar360.com/article/scenic-biotech-appoints-renowned-neurology-drug-development-leader-dr-judith-wal-e6c409ade4de9fa6PharmaRadar360en2026-09-10T07:51:03.000ZScenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officerhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-6-september-2026-10a6be24e936e540PharmaRadar360en2026-09-10T07:34:29.000ZWeekly all-cause mortality surveillance: week ending 6 September 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-820ecbff0a7a966cPharmaRadar360en2026-09-10T07:29:12.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to April to June 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-335870a76488db42PharmaRadar360en2026-09-10T07:28:52.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to January to March 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-ae1ac0815b2896b3PharmaRadar360en2026-09-10T07:27:39.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to October to December 2026https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-quarterly-data-up-bfc75e0710215140PharmaRadar360en2026-09-10T07:26:59.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: quarterly data up to July to September 2026https://www.pharmaradar360.com/article/hhs-names-permanent-leaders-of-fda-drug-and-vaccine-centers-setting-the-directio-a1123af1f2b72c44PharmaRadar360en2026-09-10T07:19:45.000ZHHS Names Permanent Leaders of FDA Drug and Vaccine Centers, Setting the Direction for Future Reviewshttps://www.pharmaradar360.com/article/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approve-0b079b33cbbfd08dPharmaRadar360en2026-09-10T07:00:55.000ZGSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved in Japanhttps://www.pharmaradar360.com/article/insilico-medicine-begins-phase-iii-trial-of-ai-discovered-drug-rentosertib-for-i-dadb1e5c66814ac8PharmaRadar360en2026-09-10T06:46:29.000ZInsilico Medicine Begins Phase III Trial of AI-Discovered Drug Rentosertib for IPFhttps://www.pharmaradar360.com/article/psi-cro-to-present-agile-models-for-emerging-biotech-at-oct-new-england-833dc325de531768PharmaRadar360en2026-09-10T06:46:29.000ZPSI CRO to Present Agile Models for Emerging Biotech at OCT New Englandhttps://www.pharmaradar360.com/article/seismic-pharmaceuticals-enrolls-first-patient-in-phase-3-trial-of-istaroxime-for-2b1bb847cd17d245PharmaRadar360en2026-09-10T06:46:29.000ZSeismic Pharmaceuticals Enrolls First Patient in Phase 3 Trial of Istaroxime for Cardiogenic Shockhttps://www.pharmaradar360.com/article/genencell-scandal-revives-korea-s-kosdaq-bio-rout-as-trust-erodes-and-risk-mount-fb54093710b5acb6PharmaRadar360en2026-09-10T06:31:00.000ZGenencell scandal revives Korea’s KOSDAQ bio rout as trust erodes and risk mounts - CHOSUNBIZhttps://www.pharmaradar360.com/article/chinese-salmon-by-products-targeted-in-12-8m-biotech-deal-c8108b005d948e22PharmaRadar360en2026-09-10T05:04:03.000ZChinese salmon by-products targeted in €12.8m biotech dealhttps://www.pharmaradar360.com/article/u-s-fda-grants-priority-review-for-roche-s-enspryng-for-mogad-an-autoimmune-dise-74fecb34511c53e2PharmaRadar360en2026-09-10T05:00:00.000ZU.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatmentshttps://www.pharmaradar360.com/article/stavros-nicolaou-represents-aspen-at-the-9th-annual-sadc-industrialisation-week-07118bf02b625030PharmaRadar360en2026-09-10T05:00:00.000ZStavros Nicolaou represents Aspen at the 9th Annual SADC Industrialisation Weekhttps://www.pharmaradar360.com/article/finnish-aq-biotech-raises-2-5m-to-scale-cancer-screening-in-china-4d00cc33ac6dddf2PharmaRadar360en2026-09-10T04:29:20.000ZFinnish AQ Biotech raises €2.5M to scale cancer screening in Chinahttps://www.pharmaradar360.com/article/harbour-biomed-advances-long-acting-antibody-candidate-to-phase-3-trial-bb7175ea04a5f45ePharmaRadar360en2026-09-10T03:42:59.000ZHarbour BioMed advances long-acting antibody candidate to Phase 3 trialhttps://www.pharmaradar360.com/article/kelun-biotech-partner-reports-positive-asthma-phase-2-trial-results-1881334f1adeeee7PharmaRadar360en2026-09-10T03:34:57.000ZKelun-Biotech partner reports positive asthma Phase 2 trial resultshttps://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-remede-system-7f6e3ec0b271b2e3PharmaRadar360en2026-09-10T03:00:00.000Z[SHINSA]English Translation of Review Report: remedē Systemhttps://www.pharmaradar360.com/article/kenanga-investment-bank-introduces-world-s-first-hang-seng-biotech-index-structu-2d2c97ee8f163699PharmaRadar360en2026-09-10T02:54:34.000ZKenanga Investment Bank Introduces World’s First Hang Seng Biotech Index Structured Warrants to Malaysiahttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32PharmaRadar360en2026-09-10T02:49:40.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/nanjing-zhongchun-biotech-rooted-in-the-ancient-capital-a-reliable-partner-in-fi-f233ef0f32fa8f8aPharmaRadar360en2026-09-10T02:36:29.000ZNanjing Zhongchun Biotech: Rooted in the Ancient Capital, a Reliable Partner in Fine Chemicalshttps://www.pharmaradar360.com/article/aces-alumna-employs-biotech-to-create-sustainable-livestock-production-d26bebab03c30cc8PharmaRadar360en2026-09-10T02:23:35.000ZACES Alumna Employs Biotech to Create Sustainable Livestock Productionhttps://www.pharmaradar360.com/article/insilico-medicine-doses-first-patient-in-genesis-ipf-3-the-world-s-first-phase-i-e40660aaa25393abPharmaRadar360en2026-09-10T00:30:00.000ZInsilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drughttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-8ba97a7835048b0dPharmaRadar360en2026-09-10T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-29706f5bf24237ffPharmaRadar360en2026-09-10T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-5e0d92994d60f5a4PharmaRadar360en2026-09-10T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-d81b0bf746dea1d5PharmaRadar360en2026-09-10T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-bed409cbf5ace142PharmaRadar360en2026-09-10T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-0a8fecb54a3fc423PharmaRadar360en2026-09-10T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-8ecf642e68d895e2PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-1f9381361a06f286PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-fbc5f4932d6017a5PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-9b2cd91149447d39PharmaRadar360en2026-09-10T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-099ad11c1b7cf6fdPharmaRadar360en2026-09-10T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-af717744324c797aPharmaRadar360en2026-09-10T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-55971ce00f6a5b47PharmaRadar360en2026-09-10T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-7c0c91083a2a7674PharmaRadar360en2026-09-10T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-0da438f85c422491PharmaRadar360en2026-09-10T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/green-innovation-gmbh-withdrawal-of-food-additive-petition-animal-use-d90074417ad7c799PharmaRadar360en2026-09-10T00:00:00.000ZGreen Innovation GmbH; Withdrawal of Food Additive Petition (Animal Use)https://www.pharmaradar360.com/article/fee-rate-for-using-a-priority-review-voucher-in-fiscal-year-2027-091f27d76fcd85b3PharmaRadar360en2026-09-10T00:00:00.000ZFee Rate for Using a Priority Review Voucher in Fiscal Year 2027https://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-2abdf53dea0a6290PharmaRadar360en2026-09-10T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/national-center-for-advancing-translational-sciences-notice-of-public-online-rou-60eabdf6f3844b70PharmaRadar360en2026-09-10T00:00:00.000ZNational Center for Advancing Translational Sciences; Notice of Public Online Roundtablehttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-mechanical-deviatio-e4a18073cc69ba43PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Mechanical Deviation Device for Esophageal Protection During Cardiac Ablation Procedureshttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-temperature-regulat-1550b33975ad5831PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Temperature Regulation Device for Esophageal Protection During Cardiac Ablation Procedureshttps://www.pharmaradar360.com/article/medical-devices-cardiovascular-devices-classification-of-the-extravascular-suppo-cc4f76058ba83528PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Cardiovascular Devices; Classification of the Extravascular Support for an Arteriovenous Fistula for Vascular Accesshttps://www.pharmaradar360.com/article/medical-devices-clinical-chemistry-and-clinical-toxicology-devices-classificatio-95c9753661159e4cPharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody Test System for Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/medical-devices-ear-nose-and-throat-devices-classification-of-the-cooperative-po-053f86715c0fa357PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Ear, Nose, and Throat Devices; Classification of the Cooperative Powered Surgical Assist Device for ENT Surgeryhttps://www.pharmaradar360.com/article/medical-devices-gastroenterology-urology-devices-classification-of-the-implanted-19651965512a4fdcPharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Gastroenterology-Urology Devices; Classification of the Implanted Tibial Electrical Urinary Continence Devicehttps://www.pharmaradar360.com/article/medical-devices-radiology-devices-classification-of-the-vaginal-hydrogel-packing-cf0bb5f7ee0efe46PharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; Radiology Devices; Classification of the Vaginal Hydrogel Packing Systemhttps://www.pharmaradar360.com/article/medical-devices-general-hospital-and-personal-use-devices-classification-of-the-e53ed8cdd83debacPharmaRadar360en2026-09-10T00:00:00.000ZMedical Devices; General Hospital and Personal Use Devices; Classification of the Whole Room Microbial Reduction Devicehttps://www.pharmaradar360.com/article/notice-of-supplemental-funding-medicare-rural-hospital-flexibility-program-bc670a4d8a9047aaPharmaRadar360en2026-09-10T00:00:00.000ZNotice of Supplemental Funding, Medicare Rural Hospital Flexibility Programhttps://www.pharmaradar360.com/article/announcing-the-intent-to-award-a-single-source-supplement-to-the-senior-medicare-1c16ee7d1b83e6c7PharmaRadar360en2026-09-10T00:00:00.000ZAnnouncing the Intent To Award a Single-Source Supplement to the Senior Medicare Patrol (SMP) Resource Centerhttps://www.pharmaradar360.com/article/short-term-efficacy-of-tegoprazan-compared-with-esomeprazole-in-patients-with-no-52cea9f1e59c7bc3PharmaRadar360en2026-09-10T00:00:00.000ZShort-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trialhttps://www.pharmaradar360.com/article/the-function-of-angiotensin-converting-enzyme-inhibitors-in-chronic-kidney-disea-8f6ef8fb6d240f67PharmaRadar360en2026-09-10T00:00:00.000ZThe Function of Angiotensin-Converting Enzyme Inhibitors in Chronic Kidney Disease: Pathophysiological Mechanisms and Implications for Practicehttps://www.pharmaradar360.com/article/proposals-for-individually-safe-and-realistic-correction-of-antipsychotics-in-ho-05a9f8821c95edf5PharmaRadar360en2026-09-10T00:00:00.000ZProposals for Individually Safe and Realistic Correction of Antipsychotics in Hospitalized Patients with Schizophrenia: A Prescription Survey at Nagoya University Hospitalhttps://www.pharmaradar360.com/article/development-of-a-rubric-for-assessing-essential-basic-social-skills-required-at-0a0ac5300f3dfbc9PharmaRadar360en2026-09-10T00:00:00.000ZDevelopment of a Rubric for Assessing Essential “Basic Social Skills” Required at the Time of Employment and Its Evaluation in Clinical Traininghttps://www.pharmaradar360.com/article/clinical-evaluation-of-reduced-dose-versus-standard-dose-remdesivir-in-patients-65b51af77de0a252PharmaRadar360en2026-09-10T00:00:00.000ZClinical Evaluation of Reduced-Dose versus Standard-Dose Remdesivir in Patients with eGFR &lt; 30 mL/min/1.73m&lt;sup&gt;2&lt;/sup&gt;: Effectiveness and Safetyhttps://www.pharmaradar360.com/article/characteristics-of-medication-errors-prevented-by-community-pharmacists-during-t-8fd3fea7f73d36c4PharmaRadar360en2026-09-10T00:00:00.000ZCharacteristics of Medication Errors Prevented by Community Pharmacists During Transition of Carehttps://www.pharmaradar360.com/article/pharmacist-secondment-implementation-of-ward-based-pharmaceutical-services-and-c-c92b42fe2d16eb49PharmaRadar360en2026-09-10T00:00:00.000ZPharmacist Secondment, Implementation of Ward-based Pharmaceutical Services, and Challenges in Medication Information Sharing during Care Transitionshttps://www.pharmaradar360.com/article/continuous-intervention-by-an-antimicrobial-stewardship-pharmacist-contributes-t-046de463fe7b026cPharmaRadar360en2026-09-10T00:00:00.000ZContinuous Intervention by an Antimicrobial Stewardship Pharmacist Contributes to Successful Treatment of a Brain Abscess: A Case Reporthttps://www.pharmaradar360.com/article/identification-of-risk-factors-for-lithium-associated-renal-impairment-a-multice-5f41a254316a4f7aPharmaRadar360en2026-09-10T00:00:00.000ZIdentification of Risk Factors for Lithium-Associated Renal Impairment: A Multicenter Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/evaluation-of-treatment-continuation-and-tolerability-using-the-urine-protein-to-7d9c0f2639c5f082PharmaRadar360en2026-09-10T00:00:00.000ZEvaluation of Treatment Continuation and Tolerability Using the Urine Protein-to-Creatinine Ratio (UPC Ratio) as a Criterion for Proteinuria in Patients with Colorectal Cancer Receiving Bevacizumabhttps://www.pharmaradar360.com/article/implementation-of-the-electronic-tracing-report-system-and-evaluation-of-its-use-71b92bcdcc397e3bPharmaRadar360en2026-09-10T00:00:00.000ZImplementation of the Electronic Tracing Report System and Evaluation of its Usefulnesshttps://www.pharmaradar360.com/article/epidemiology-of-acute-kidney-injury-aki-and-sepsis-associated-aki-in-critically-b6d5977523dd237cPharmaRadar360en2026-09-10T00:00:00.000ZEpidemiology of acute kidney injury (AKI) and sepsis-associated AKI in critically ill patients: A retrospective cohort studyhttps://www.pharmaradar360.com/article/the-effect-of-a-telephonic-reminder-on-fasting-duration-in-children-undergoing-c-81dd7d56c74043e5PharmaRadar360en2026-09-10T00:00:00.000ZThe effect of a telephonic reminder on fasting duration in children undergoing computed tomography scan under sedation in a resource-limited setting – A randomized controlled trialhttps://www.pharmaradar360.com/article/comparative-evaluation-of-sternomental-and-hyomental-distance-based-dynamic-airw-9b0a21c89b21e9a8PharmaRadar360en2026-09-10T00:00:00.000ZComparative evaluation of sternomental and hyomental distance–based dynamic airway indices for predicting difficult laryngoscopy in obese surgical patients: A prospective observational studyhttps://www.pharmaradar360.com/article/phantom-plethysmography-a-pulse-oximeter-artifact-caused-by-ambient-light-9d789979f52ddb2dPharmaRadar360en2026-09-10T00:00:00.000ZPhantom plethysmography: A pulse oximeter artifact caused by ambient lighthttps://www.pharmaradar360.com/article/thoracic-continuous-spinal-anesthesia-for-prolonged-thoracolumbar-fixation-and-k-39160d2fd342c76ePharmaRadar360en2026-09-10T00:00:00.000ZThoracic continuous spinal anesthesia for prolonged thoracolumbar fixation and kyphoplasty in a high-risk geriatric patient with severe pulmonary comorbidityhttps://www.pharmaradar360.com/article/morphine-ketamine-combination-for-acute-trauma-analgesia-unanswered-questions-be-a688b64ea7fdcefbPharmaRadar360en2026-09-10T00:00:00.000ZMorphine–ketamine combination for acute trauma analgesia: Unanswered questions beyond the meta-analysishttps://www.pharmaradar360.com/article/therapeutic-responses-and-6-month-clinical-outcomes-in-sarcoidosis-a-longitudina-1dfb2b94343d3422PharmaRadar360en2026-09-10T00:00:00.000ZTherapeutic Responses and 6-month Clinical Outcomes in Sarcoidosis: A Longitudinal Study in a Tertiary South Indian Cohorthttps://www.pharmaradar360.com/article/electrotherapy-in-pediatric-rehabilitation-a-structured-narrative-review-of-clin-d2236a91b304d8e6PharmaRadar360en2026-09-10T00:00:00.000ZElectrotherapy in Pediatric Rehabilitation: A Structured Narrative Review of Clinical Applications, Treatment Parameters, Safety, and Evidence Gapshttps://www.pharmaradar360.com/article/cbct-based-anatomical-assessment-of-lingual-bone-availability-relevant-to-the-me-4d89c9009e1b662aPharmaRadar360en2026-09-10T00:00:00.000ZCBCT-Based Anatomical Assessment of Lingual Bone Availability Relevant to the Mental Foramen Bypass Concept in Posterior Atrophied Mandibleshttps://www.pharmaradar360.com/article/personality-and-coming-to-terms-with-cancer-a-cross-sectional-study-of-five-fact-0ead1686b1643e4bPharmaRadar360en2026-09-10T00:00:00.000ZPersonality and Coming to Terms with Cancer: A Cross-Sectional Study of Five-Factor Traits and Illness Acceptance in Oncology Outpatientshttps://www.pharmaradar360.com/article/circulating-interleukin-17-across-airway-disease-phenotypes-a-single-center-obse-2fdf11ea2437bca3PharmaRadar360en2026-09-10T00:00:00.000ZCirculating Interleukin-17 Across Airway Disease Phenotypes: A Single-Center Observational Studyhttps://www.pharmaradar360.com/article/impact-of-age-on-success-of-3d-printed-cranial-remolding-orthoses-for-deformatio-9aa46e3dc891e64dPharmaRadar360en2026-09-10T00:00:00.000ZImpact of Age on Success of 3D-Printed Cranial Remolding Orthoses for Deformational Head Shapeshttps://www.pharmaradar360.com/article/exercise-induced-bronchoconstriction-in-school-aged-children-born-very-preterm-p-ae54f67e30689774PharmaRadar360en2026-09-10T00:00:00.000ZExercise-Induced Bronchoconstriction in School-Aged Children Born Very Preterm: Prevalence and Associated Clinical Factorshttps://www.pharmaradar360.com/article/multilevel-mechanisms-and-clinical-efficacy-of-psilocybin-in-depression-treatmen-c152eb701a32b92cPharmaRadar360en2026-09-10T00:00:00.000ZMultilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Reviewhttps://www.pharmaradar360.com/article/user-centered-design-approach-to-dynamic-clinical-decision-support-in-primary-pr-311b856abb73970dPharmaRadar360en2026-09-10T00:00:00.000ZUser-Centered Design Approach to Dynamic Clinical Decision Support in Primary Prevention of Cardiovascular Diseasehttps://www.pharmaradar360.com/article/comment-on-huang-et-al-accuracy-and-agreement-of-a-45-mg-versus-a-75-mg-13c-urea-c3adf5d3af9f3d93PharmaRadar360en2026-09-10T00:00:00.000ZComment on Huang et al. Accuracy and Agreement of a 45 mg Versus a 75 mg 13C-Urea Breath Test for the Diagnosis of Helicobacter pylori Infection in Adults: A Randomized Crossover Trial. Diagnostics 2026, 16, 1567https://www.pharmaradar360.com/article/clinical-outcomes-and-new-treatments-in-pediatric-brain-tumors-a7ae81bda7df0329PharmaRadar360en2026-09-10T00:00:00.000ZClinical Outcomes and New Treatments in Pediatric Brain Tumorshttps://www.pharmaradar360.com/article/from-mitochondrial-support-to-mitohormetic-readiness-a-micronutrient-centric-ext-f324d9fbecf27cf9PharmaRadar360en2026-09-10T00:00:00.000ZFrom Mitochondrial Support to Mitohormetic Readiness: A Micronutrient-Centric Extension of the Energy Allocation Systemhttps://www.pharmaradar360.com/article/impact-of-ethanol-sclerotherapy-on-pelvic-pain-and-quality-of-life-in-patients-w-272a8ec4a97d9120PharmaRadar360en2026-09-10T00:00:00.000ZImpact of ethanol sclerotherapy on pelvic pain and quality of life in patients with endometriomas (ESCOMA study): protocol for a randomised clinical trialhttps://www.pharmaradar360.com/article/comparison-of-live-birth-rates-between-calorie-restricted-diet-and-metformin-pri-e6f52d6cd1926e2dPharmaRadar360en2026-09-10T00:00:00.000ZComparison of live birth rates between calorie-restricted diet and metformin prior to ovulation induction therapy in women with polycystic ovary syndrome and overweight/obesity: a protocol for a multicenter, randomized comparative effectiveness trialhttps://www.pharmaradar360.com/article/shunt-pathophysiological-mechanisms-and-clinical-implications-of-ineffective-cir-3955f02cf56865e4PharmaRadar360en2026-09-10T00:00:00.000ZShunt: pathophysiological mechanisms and clinical implications of ineffective circulating volumehttps://www.pharmaradar360.com/article/hypericin-and-hyperforin-from-st-john-s-wort-are-potent-intestinal-ugt-inhibitor-10d289e1efb49df5PharmaRadar360en2026-09-10T00:00:00.000ZHypericin and hyperforin from St. John’s Wort are potent intestinal UGT inhibitors with distinct binding modes: mechanistic and quantitative prediction of clinical drug–drug interaction riskhttps://www.pharmaradar360.com/article/foxc1-drives-lung-cancer-metastasis-and-functions-as-a-target-for-ai-enabled-ant-1defa9cda85e5e4fPharmaRadar360en2026-09-10T00:00:00.000ZFOXC1 drives lung cancer metastasis and functions as a target for AI-enabled anti-metastatic drug discoveryhttps://www.pharmaradar360.com/article/beyond-a-negative-trial-timing-molecular-residual-disease-and-antibody-biology-i-bb05374d7dd1fb5ePharmaRadar360en2026-09-10T00:00:00.000ZBeyond a negative trial: timing, molecular residual disease, and antibody biology in adjuvant immunotherapy for resected NSCLChttps://www.pharmaradar360.com/article/acupuncture-for-chronic-tinnitus-study-protocol-for-a-clinical-trial-with-audito-8863c954452a2b82PharmaRadar360en2026-09-10T00:00:00.000ZAcupuncture for chronic tinnitus: study protocol for a clinical trial with auditory brainstem response outcomeshttps://www.pharmaradar360.com/article/control-effect-of-dual-mechanism-myopia-control-lenses-on-myopia-in-children-and-7da4cb5525ea95aaPharmaRadar360en2026-09-10T00:00:00.000ZControl effect of dual-mechanism myopia control lenses on myopia in children and adolescents: a prospective, 12-month, non-randomized, parallel-controlled, and single-center trial protocolhttps://www.pharmaradar360.com/article/clinical-warrant-in-medical-llm-evaluation-459f9d52d16df761PharmaRadar360en2026-09-10T00:00:00.000ZClinical warrant in medical LLM evaluationhttps://www.pharmaradar360.com/article/presidential-inaugural-address-2026-expanding-computer-based-testing-strengtheni-15fe341fe4ecbd79PharmaRadar360en2026-09-10T00:00:00.000ZPresidential inaugural address 2026: expanding computer-based testing, strengthening clinical competency assessment, and adopting artificial intelligence with caution in health professions licensing examinations in Koreahttps://www.pharmaradar360.com/article/larval-density-development-and-distribution-of-costelytra-giveni-in-a-first-year-dfa5c9918d6a640aPharmaRadar360en2026-09-10T00:00:00.000ZLarval density, development, and distribution of Costelytra giveni in a first-year ryegrass–endophyte grazing trialhttps://www.pharmaradar360.com/article/one-year-comparison-of-three-maintenance-doses-of-vitamin-d3-600-1000-and-2000-i-7d271c298d361625PharmaRadar360en2026-09-10T00:00:00.000ZOne-Year Comparison of Three Maintenance Doses of Vitamin D₃ (600, 1000, and 2000 IU/day) on Metabolic Outcomes in Overweight and Obese Children: A Post-Hoc Analysis of a Randomized Trialhttps://www.pharmaradar360.com/article/drug-drug-interactions-and-pharmacological-complexity-as-prognostic-determinants-36411921172495c4PharmaRadar360en2026-09-10T00:00:00.000ZDrug–Drug Interactions and Pharmacological Complexity as Prognostic Determinants in Advanced Cholangiocarcinoma: A Real- World Study of the Drug-PIN® Scorehttps://www.pharmaradar360.com/article/when-thyrotropin-meets-growth-hormone-clinical-challenges-of-a-mixed-gh-tsh-secr-582838b0171f14b7PharmaRadar360en2026-09-10T00:00:00.000ZWhen Thyrotropin Meets Growth Hormone: Clinical Challenges of a Mixed GH/TSH-Secreting PIT1-Lineage Pituitary Neuroendocrine Tumorhttps://www.pharmaradar360.com/article/indications-of-a-dependent-invention-for-the-use-of-which-a-compulsory-license-m-090bbb27c034b7e9PharmaRadar360en2026-09-10T00:00:00.000ZIndications of a Dependent Invention for the Use of which a Compulsory License May be Granted in the Pharmaceutical Fieldhttps://www.pharmaradar360.com/article/procedural-and-clinical-outcomes-of-second-generation-robotic-assisted-versus-ma-2ff0a102943ed8cdPharmaRadar360en2026-09-10T00:00:00.000ZProcedural and Clinical Outcomes of Second-generation Robotic-assisted versus Manual Percutaneous Coronary Intervention: A 1-year Follow-up Studyhttps://www.pharmaradar360.com/article/cardiac-troponin-in-pediatric-cardiology-toward-standardized-interpretive-framew-c21aedff40641d2dPharmaRadar360en2026-09-10T00:00:00.000ZCardiac troponin in pediatric cardiology: toward standardized interpretive frameworks and clinical decision limitshttps://www.pharmaradar360.com/article/a-comparative-evaluation-of-p-tau217-stability-in-serum-and-plasma-using-two-val-e3b099e3c956cdd5PharmaRadar360en2026-09-10T00:00:00.000ZA comparative evaluation of p-tau217 stability in serum and plasma using two validated assayshttps://www.pharmaradar360.com/article/din-spec-91532-a-process-oriented-framework-for-quality-assurance-in-clinical-ma-af7479e9fd68713ePharmaRadar360en2026-09-10T00:00:00.000ZDIN SPEC 91532: a process-oriented framework for quality assurance in clinical mass spectrometryhttps://www.pharmaradar360.com/article/clinical-factors-related-to-cardiac-conduction-disturbance-in-patients-with-wild-1960f220eca28d40PharmaRadar360en2026-09-10T00:00:00.000ZClinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatmenthttps://www.pharmaradar360.com/article/clinical-impact-of-hospital-associated-disability-in-patients-with-acute-decompe-5990a34ce35f7358PharmaRadar360en2026-09-10T00:00:00.000ZClinical Impact of Hospital-Associated Disability in Patients With Acute Decompensated Heart Failurehttps://www.pharmaradar360.com/article/high-intensity-statins-and-the-post-discharge-clinical-outcomes-at-1-year-after-6772e5c513209acaPharmaRadar360en2026-09-10T00:00:00.000ZHigh-Intensity Statins and the Post-Discharge Clinical Outcomes at 1 Year After Percutaneous Coronary Intervention ― Insights From STOPDAPT-3 ―https://www.pharmaradar360.com/article/endomyocardial-biopsy-and-clinical-outcomes-in-acute-myocarditis-multicenter-coh-ad26290eeb8a3c67PharmaRadar360en2026-09-10T00:00:00.000ZEndomyocardial Biopsy and Clinical Outcomes in Acute Myocarditis ― Multicenter Cohort Study ―https://www.pharmaradar360.com/article/detection-of-crystalline-ibuprofen-components-in-ibuprofen-loaded-sba-15-mesopor-7138db2e1588d3b6PharmaRadar360en2026-09-10T00:00:00.000ZDetection of Crystalline Ibuprofen Components in Ibuprofen-Loaded SBA-15 Mesoporous Silica Using Time-Domain NMRhttps://www.pharmaradar360.com/article/evaluation-of-water-related-lt-i-gt-t-lt-i-gt-lt-sub-gt-2-lt-sub-gt-relaxation-b-0d37b85783605e80PharmaRadar360en2026-09-10T00:00:00.000ZEvaluation of Water-Related &lt;i&gt;T&lt;/i&gt;&lt;sub&gt;2&lt;/sub&gt; Relaxation Behavior in Hot-Melt Extruded Clotrimazole/PVPVA Solid Dispersions Using Time-Domain NMRhttps://www.pharmaradar360.com/article/exploring-the-therapeutic-impact-of-targeting-brk-in-epithelial-derived-cancer-c-de1a23859be6977ePharmaRadar360en2026-09-10T00:00:00.000ZExploring the Therapeutic Impact of Targeting Brk in Epithelial-Derived Cancer Cellshttps://www.pharmaradar360.com/article/realgar-transforming-solution-triggers-ferroptosis-associated-death-in-nb4-leuke-a1c5b8ee91dfa235PharmaRadar360en2026-09-10T00:00:00.000ZRealgar Transforming Solution Triggers Ferroptosis-Associated Death in NB4 Leukemia Cells through Disruption of Iron Homeostasis and Suppression of the SLC7A11/GPX4 Axishttps://www.pharmaradar360.com/article/critical-medicines-lists-in-japan-and-the-european-union-insights-into-supply-re-b3c63434f9bb8e7dPharmaRadar360en2026-09-10T00:00:00.000ZCritical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Prioritieshttps://www.pharmaradar360.com/article/hydrophobic-compounds-in-the-lt-i-gt-paeonia-suffruticosa-lt-i-gt-root-cortex-re-fcc2875b79003b62PharmaRadar360en2026-09-10T00:00:00.000ZHydrophobic Compounds in the &lt;i&gt;Paeonia suffruticosa&lt;/i&gt; Root Cortex Reduce Lipid Accumulation in Adipocytes and the Livers of Obese &lt;i&gt;ob&lt;/i&gt;/&lt;i&gt;ob&lt;/i&gt; Micehttps://www.pharmaradar360.com/article/153abr-clinical-procedure-applications-d0e4148b0fd3773bPharmaRadar360en2026-09-10T00:00:00.000Z153ABR: Clinical Procedure Applicationshttps://www.pharmaradar360.com/article/erratum-safety-tolerability-and-antitumor-activity-of-zipalertinib-among-patient-9348373953769dbaPharmaRadar360en2026-09-10T00:00:00.000ZErratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertionshttps://www.pharmaradar360.com/article/erratum-efficacy-and-safety-of-anselamimab-in-immunoglobulin-light-chain-amyloid-94141529a1094132PharmaRadar360en2026-09-10T00:00:00.000ZErratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trialshttps://www.pharmaradar360.com/article/therapy-for-stage-iv-non-small-cell-lung-cancer-with-driver-alterations-asco-liv-959d85f1292c4974PharmaRadar360en2026-09-10T00:00:00.000ZTherapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2https://www.pharmaradar360.com/article/reply-to-role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-p-775da0d78d9dcbd0PharmaRadar360en2026-09-10T00:00:00.000ZReply to: Role of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriershttps://www.pharmaradar360.com/article/reply-to-olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-depende-d2c1227aecb440baPharmaRadar360en2026-09-10T00:00:00.000ZReply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacyhttps://www.pharmaradar360.com/article/intismeran-autogene-plus-pembrolizumab-versus-pembrolizumab-alone-in-high-risk-r-d4126ebab8f61724PharmaRadar360en2026-09-10T00:00:00.000ZIntismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Studyhttps://www.pharmaradar360.com/article/he-was-always-there-f0fcbcf89c659ca0PharmaRadar360en2026-09-10T00:00:00.000ZHe Was Always Therehttps://www.pharmaradar360.com/article/olaparib-in-metastatic-breast-cancer-the-impact-of-prior-cyclin-dependent-kinase-df42a6f811bc75a6PharmaRadar360en2026-09-10T00:00:00.000ZOlaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacyhttps://www.pharmaradar360.com/article/combi-i-long-term-overall-survival-with-spartalizumab-plus-dabrafenib-and-tramet-952659f5b36f2fcfPharmaRadar360en2026-09-10T00:00:00.000ZCOMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Advanced Melanomahttps://www.pharmaradar360.com/article/role-of-risk-reducing-bilateral-mastectomy-in-i-brca1-i-and-i-brca2-i-pathogenic-82dafac178eac60bPharmaRadar360en2026-09-10T00:00:00.000ZRole of Risk-Reducing Bilateral Mastectomy in <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriershttps://www.pharmaradar360.com/article/developing-a-histology-based-artificial-intelligence-biomarker-to-predict-adjuva-7a52e5237fb6ed1fPharmaRadar360en2026-09-10T00:00:00.000ZDeveloping a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancerhttps://www.pharmaradar360.com/article/should-artificial-intelligence-direct-systemic-therapy-decisions-in-pancreatic-c-c4a0a33b2312faedPharmaRadar360en2026-09-10T00:00:00.000ZShould Artificial Intelligence Direct Systemic Therapy Decisions in Pancreatic Cancer?https://www.pharmaradar360.com/article/sustaining-high-reliability-amid-artificial-intelligence-adoption-in-oncology-593d81fb37071e65PharmaRadar360en2026-09-10T00:00:00.000ZSustaining High Reliability Amid Artificial Intelligence Adoption in Oncologyhttps://www.pharmaradar360.com/article/oncology-drug-development-challenges-of-increasingly-available-therapies-ca545af2dd113f6fPharmaRadar360en2026-09-10T00:00:00.000ZOncology Drug Development: Challenges of Increasingly Available Therapieshttps://www.pharmaradar360.com/article/impact-of-tumor-genomic-profile-on-adjuvant-chemotherapy-efficacy-in-resected-pa-3334b8a840da9cbePharmaRadar360en2026-09-10T00:00:00.000ZImpact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Studyhttps://www.pharmaradar360.com/article/development-and-validation-of-a-computational-histology-artificial-intelligence-ea25f506da3e0dd0PharmaRadar360en2026-09-10T00:00:00.000ZDevelopment and Validation of a Computational Histology Artificial Intelligence–Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancerhttps://www.pharmaradar360.com/article/phase-ii-clinical-study-of-adebrelimab-and-bevacizumab-combined-with-cisplatin-c-c6e26ef3d70cbaeaPharmaRadar360en2026-09-10T00:00:00.000ZPhase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)https://www.pharmaradar360.com/article/magrolimab-plus-azacitidine-versus-placebo-plus-azacitidine-in-patients-with-unt-f50f60a602c26239PharmaRadar360en2026-09-10T00:00:00.000ZMagrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Studyhttps://www.pharmaradar360.com/article/spotlighting-rising-researcher-lucas-attia-from-drug-nanoparticle-engineering-to-80d678c9fb2b6243PharmaRadar360en2026-09-10T00:00:00.000ZSpotlighting rising researcher Lucas Attia: from drug nanoparticle engineering to molecular property predictionhttps://www.pharmaradar360.com/article/comparative-changes-in-cardiovascular-measures-following-speed-agility-and-quick-7d38e12c591165cbPharmaRadar360en2026-09-10T00:00:00.000ZComparative changes in cardiovascular measures following speed, agility, and quickness training and small-sided games in youth football players: a randomized trialhttps://www.pharmaradar360.com/article/comparison-of-two-tooth-whitening-treatments-a-randomized-split-mouth-clinical-t-c0c6e1e2d0ef8771PharmaRadar360en2026-09-10T00:00:00.000ZComparison of two tooth whitening treatments: a randomized split-mouth clinical trialhttps://www.pharmaradar360.com/article/a-clinical-prediction-model-for-self-harm-after-adolescent-traumatic-brain-injur-e24ad5ae8d0cc3ddPharmaRadar360en2026-09-10T00:00:00.000ZA Clinical Prediction Model for Self-Harm After Adolescent Traumatic Brain Injuryhttps://www.pharmaradar360.com/article/the-development-and-initial-validation-of-the-perinatal-intrusions-interpretatio-e0c5c555f7035197PharmaRadar360en2026-09-10T00:00:00.000ZThe development and initial validation of the Perinatal Intrusions Interpretation Index: A novel scale that measures negative appraisals of infant‐related intrusive thoughtshttps://www.pharmaradar360.com/article/the-influence-of-social-media-on-users-intention-to-participate-in-clinical-tria-e5c75968b8839648PharmaRadar360en2026-09-10T00:00:00.000ZThe influence of social media on users’ intention to participate in clinical trials: a cross-country analysis using an adapted technology acceptance modelhttps://www.pharmaradar360.com/article/price-gouging-in-the-b2b-pharmaceutical-market-a-systematic-review-of-unethical-c525db114cfe942aPharmaRadar360en2026-09-10T00:00:00.000ZPrice gouging in the B2B pharmaceutical market: a systematic review of unethical pricing, market manipulation, and regulatory challengeshttps://www.pharmaradar360.com/article/hypnosis-for-postoperative-pain-management-following-colectomies-a-single-center-2399ea4259a39d8ePharmaRadar360en2026-09-10T00:00:00.000ZHypnosis for Postoperative Pain Management Following Colectomies: A Single-Center Randomized Controlled Feasibility Trialhttps://www.pharmaradar360.com/article/a-user-centric-patient-educational-intervention-in-clinical-practice-helping-wom-65d17fa745ccd8e6PharmaRadar360en2026-09-10T00:00:00.000ZA user-centric patient educational intervention in clinical practice: helping women to learn and share experiences about menopausehttps://www.pharmaradar360.com/article/silk-sericin-fibroin-composite-drug-delivery-systems-for-lung-cancer-mechanistic-8a8fa26cb15838c7PharmaRadar360en2026-09-10T00:00:00.000ZSilk sericin/fibroin composite drug delivery systems for lung cancer: mechanistic Rationale, potential functional complementarity, and future perspectiveshttps://www.pharmaradar360.com/article/when-fear-became-the-barrier-to-care-lessons-of-a-clinical-rapid-response-during-40975bffd5c0cbd9PharmaRadar360en2026-09-10T00:00:00.000ZWhen Fear Became the Barrier to Care — Lessons of a Clinical Rapid Response during Operation Metro Surgehttps://www.pharmaradar360.com/article/a-virtual-reality-cardiopulmonary-bypass-simulator-versus-conventional-halstedia-ac64a873d60ef83cPharmaRadar360en2026-09-10T00:00:00.000ZA Virtual Reality Cardiopulmonary Bypass Simulator Versus Conventional Halstedian Observation for Early Perfusion Education: A Randomised Controlled Trialhttps://www.pharmaradar360.com/article/how-lipid-ingestion-is-sensed-the-mechanisms-underlying-intestinal-hormone-secre-22afd06b3217a312PharmaRadar360en2026-09-10T00:00:00.000ZHow lipid ingestion is sensed: the mechanisms underlying intestinal hormone secretionhttps://www.pharmaradar360.com/article/differential-detection-of-tau-aggregation-species-using-a-small-molecule-probe-f-d66e0f055a747884PharmaRadar360en2026-09-10T00:00:00.000ZDifferential detection of tau aggregation species using a small molecule probe for cell-based drug screeninghttps://www.pharmaradar360.com/article/pre-treatment-prediction-of-ebv-dna-status-in-nasopharyngeal-carcinoma-using-ce-a68cbee4efda910cPharmaRadar360en2026-09-10T00:00:00.000ZPre-treatment prediction of EBV-DNA status in nasopharyngeal carcinoma using CE-T1WI radiomics combined with clinical features: a multi-sequence MRI radiomics studyhttps://www.pharmaradar360.com/article/integrating-artificial-intelligence-and-quantum-chemistry-for-sustainable-pharma-2d6f3ac18e807696PharmaRadar360en2026-09-10T00:00:00.000ZIntegrating artificial intelligence and quantum chemistry for sustainable pharmaceutical retrosynthesishttps://www.pharmaradar360.com/article/aptamer-functionalized-dna-frameworks-as-targeted-drug-buffers-for-concentration-80b9dd9403406b46PharmaRadar360en2026-09-10T00:00:00.000ZAptamer-Functionalized DNA Frameworks as Targeted Drug Buffers for Concentration Regulation of Maytansinehttps://www.pharmaradar360.com/article/an-explainable-ai-framework-for-early-mental-health-screening-and-clinical-decis-d1bcabc444546af5PharmaRadar360en2026-09-10T00:00:00.000ZAn explainable AI framework for early mental health screening and clinical decision support using reflective listening and generative AIhttps://www.pharmaradar360.com/article/trust-and-the-reliability-of-ai-algorithms-for-clinical-decision-making-support-9e4b561742c5eac6PharmaRadar360en2026-09-10T00:00:00.000ZTrust and the reliability of AI algorithms for clinical decision-making support in medicine: the MIRACLE case studyhttps://www.pharmaradar360.com/article/potenzial-und-herausforderungen-von-large-language-models-in-der-klinischen-ents-aab5af7bbb512e77PharmaRadar360en2026-09-10T00:00:00.000ZPotenzial und Herausforderungen von Large Language Models in der klinischen Entscheidungsfindunghttps://www.pharmaradar360.com/article/the-deubiquitinating-enzyme-regulatory-network-in-malignant-progression-of-breas-1ae6f24cf43a9983PharmaRadar360en2026-09-10T00:00:00.000ZThe deubiquitinating enzyme regulatory network in malignant progression of breast cancer encompasses mechanisms of action, clinical significance and emerging therapeutic targetshttps://www.pharmaradar360.com/article/clinical-laboratory-and-radiological-factors-associated-with-posterior-reversibl-ada55e4fd84835f5PharmaRadar360en2026-09-10T00:00:00.000ZClinical, Laboratory and Radiological Factors associated with posterior reversible encephalopathy syndrome (PRES) in patients with eclampsia or pre-eclampsia: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/agreement-between-artificial-intelligence-and-periodontists-in-the-detection-of-19457d539500c908PharmaRadar360en2026-09-10T00:00:00.000ZAgreement between artificial intelligence and periodontists in the detection of periodontal bone loss on panoramic radiographshttps://www.pharmaradar360.com/article/hanmi-pharmaceutical-target-price-raised-to-650-000-as-roche-deal-value-reflecte-7b981f6d3cd04d61PharmaRadar360en2026-09-09T23:35:00.000ZHanmi Pharmaceutical Target Price Raised to ₩650,000 as Roche Deal Value Reflectedhttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-after-aspire-miss-and-genglycos-win-has-valuation-3ffec4f293a82118PharmaRadar360en2026-09-09T23:28:36.000ZUltragenyx Pharmaceutical (RARE) After Aspire Miss And GENGLYCOS Win Has Valuation Back In Focushttps://www.pharmaradar360.com/article/portage-biotech-alp-financials-2026-income-statement-and-balance-sheet-alp-a532834d0e460662PharmaRadar360en2026-09-09T23:15:22.000ZPortage Biotech (ALP) Financials 2026 - Income Statement and Balance Sheet $ALPhttps://www.pharmaradar360.com/article/pharmaceutical-company-expanding-adding-jobs-in-hauppauge-d80f5da0a5cd0868PharmaRadar360en2026-09-09T23:04:28.000ZPharmaceutical company expanding, adding jobs in Hauppaugehttps://www.pharmaradar360.com/article/research-national-commission-into-the-regulation-of-ai-in-healthcare-recommendat-ebbddaf59e9d3532PharmaRadar360en2026-09-09T23:01:00.000ZResearch: National Commission into the Regulation of AI in Healthcare: Recommendations for a future regulatory frameworkhttps://www.pharmaradar360.com/article/rebuilding-mexico-s-pharmaceutical-supply-chain-3e5a86b66630a924PharmaRadar360en2026-09-09T22:42:55.000ZRebuilding Mexico's Pharmaceutical Supply Chainhttps://www.pharmaradar360.com/article/potential-pill-for-peanut-milk-egg-allergies-enters-phase-3-trial-9b77f26228e19997PharmaRadar360en2026-09-09T22:35:37.000ZPotential Pill for Peanut, Milk, Egg Allergies Enters Phase 3 Trialhttps://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-1ec522bb7e31fbaePharmaRadar360en2026-09-09T21:53:32.000ZLouisiana AG takes FDA and pharmaceutical companies to court over abortion pillshttps://www.pharmaradar360.com/article/louisiana-ag-takes-fda-and-pharmaceutical-companies-to-court-over-abortion-pills-2bbc103d0de45256PharmaRadar360en2026-09-09T21:46:51.000ZLouisiana AG takes FDA and pharmaceutical companies to court over abortion pillshttps://www.pharmaradar360.com/article/biden-era-by-mail-abortion-pills-can-t-be-halted-despite-safety-data-gap-appeals-e16ccb2f49768bd5PharmaRadar360en2026-09-09T21:39:29.000ZBiden-era, by-mail abortion pills can't be halted despite safety data 'gap,' appeals court suggestshttps://www.pharmaradar360.com/article/hhs-names-four-senior-fda-officials-in-leadership-reorganization-54cf11cc363bef01PharmaRadar360en2026-09-09T21:34:56.000ZHHS Names Four Senior FDA Officials in Leadership Reorganizationhttps://www.pharmaradar360.com/article/generation-park-is-creating-a-national-pharmaceutical-hub-in-houston-bba29ce5588183bePharmaRadar360en2026-09-09T21:10:55.000ZGeneration Park is Creating a National Pharmaceutical Hub in Houstonhttps://www.pharmaradar360.com/article/meet-annalina-che-the-scientist-behind-biotech-start-up-darkfin-labs-c8d101f77eaedcecPharmaRadar360en2026-09-09T20:08:31.000ZMeet Annalina Che, the Scientist Behind Biotech Start-up Darkfin Labshttps://www.pharmaradar360.com/article/seismic-pharmaceuticals-commences-global-phase-3-trial-of-istaroxime-in-patients-08ecec56915041b8PharmaRadar360en2026-09-09T20:05:00.000ZSeismic Pharmaceuticals Commences Global Phase 3 Trial of Istaroxime in Patients With Cardiogenic Shockhttps://www.pharmaradar360.com/article/shareholders-back-every-proposal-at-purple-biotech-ppbt-2026-meeting-8cc35989e741aa3ePharmaRadar360en2026-09-09T20:02:12.000ZShareholders back every proposal at Purple Biotech (PPBT) 2026 meetinghttps://www.pharmaradar360.com/article/technology-transfer-success-drivers-and-obstacles-explained-f93565e6205cc9ffPharmaRadar360en2026-09-09T19:36:35.000ZTechnology Transfer: Success Drivers and Obstacles Explainedhttps://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-6e6421b7f6e08843PharmaRadar360en2026-09-09T18:54:14.000ZKelun-Biotech’s Twice-Yearly Asthma Candidate SKB378 Advances into Phase IIIhttps://www.pharmaradar360.com/article/kelun-biotech-s-twice-yearly-asthma-candidate-skb378-advances-into-phase-iii-c198555d2578e70fPharmaRadar360en2026-09-09T18:35:06.000ZKelun-Biotech’s Twice-Yearly Asthma Candidate SKB378 Advances into Phase IIIhttps://www.pharmaradar360.com/article/us-appeals-court-skeptical-of-bid-to-curtail-abortion-pill-access-6e050300f86774f7PharmaRadar360en2026-09-09T18:31:44.000ZUS appeals court skeptical of bid to curtail abortion pill accesshttps://www.pharmaradar360.com/article/wall-street-slashes-dyne-therapeutics-targets-after-novartis-dm1-trial-failure-f71e254e2955835dPharmaRadar360en2026-09-09T18:24:00.000ZWall Street Slashes Dyne Therapeutics Targets After Novartis DM1 Trial Failurehttps://www.pharmaradar360.com/article/nueva-convocatoria-para-realizar-practicas-preprofesionales-0a0fa80b13f1b170PharmaRadar360en2026-09-09T18:20:00.000ZNueva convocatoria para realizar prácticas preprofesionaleshttps://www.pharmaradar360.com/article/u-s-and-tunisian-officials-break-ground-on-renovation-of-ministry-of-health-phar-ba2e86b24a145546PharmaRadar360en2026-09-09T18:19:45.000ZU.S. and Tunisian Officials Break Ground on Renovation of Ministry of Health Pharmaceutical Warehousehttps://www.pharmaradar360.com/article/leukemia-drug-data-suggested-a-different-way-to-treat-diabetes-a-new-biotech-wil-951cf12440ea5591PharmaRadar360en2026-09-09T17:57:47.000ZLeukemia drug data suggested a different way to treat diabetes. A new biotech will test that ideahttps://www.pharmaradar360.com/article/cualtos-opens-registration-for-the-bachelor-s-degree-in-pharmaceutical-chemistry-cd37687b38cd07c5PharmaRadar360en2026-09-09T17:22:54.000ZCUAltos opens registration for the Bachelor's Degree in Pharmaceutical Chemistry and Biologyhttps://www.pharmaradar360.com/article/mbrx-stock-drops-25-as-moleculin-biotech-s-interim-cancer-trial-data-falls-short-d8f025f87aa6b36fPharmaRadar360en2026-09-09T16:54:54.000ZMBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significancehttps://www.pharmaradar360.com/article/appeals-court-skeptical-that-louisiana-can-sue-fda-over-mifepristone-being-maile-a16892c426e35ef1PharmaRadar360en2026-09-09T16:51:00.000ZAppeals Court Skeptical That Louisiana Can Sue FDA Over Mifepristone Being Mailed into the Statehttps://www.pharmaradar360.com/article/news-today-satya-niketan-collapse-a-wake-up-call-to-act-but-why-wait-for-tragedi-9e4d71030a910565PharmaRadar360en2026-09-09T16:37:32.000ZNews Today: Satya Niketan collapse a wake-up call to act. But why wait for tragedies? Panellists discuss - India Todayhttps://www.pharmaradar360.com/article/pharma-s-r-d-commercial-approach-shifts-amid-global-policy-evolution-65d9e6dd72fa76dcPharmaRadar360en2026-09-09T16:35:55.000ZPharma’s R&D, commercial approach shifts amid global policy evolutionhttps://www.pharmaradar360.com/article/biotech-fluidics-releases-upgraded-degasi-inline-degasser-range-147cc76d79d3987cPharmaRadar360en2026-09-09T16:32:33.000ZBiotech Fluidics releases upgraded DEGASi inline degasser rangehttps://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-12b843a0aabf818fPharmaRadar360en2026-09-09T16:21:45.000ZBiotech firm uses space to help cells regenerate bodily structureshttps://www.pharmaradar360.com/article/biotech-firm-uses-space-to-help-cells-regenerate-bodily-structures-75ef1e4053d689b2PharmaRadar360en2026-09-09T16:21:00.000ZBiotech firm uses space to help cells regenerate bodily structureshttps://www.pharmaradar360.com/article/alpha-genesis-backs-biotech-startups-with-50m-agi-ventures-fund-99f88ef051673c6fPharmaRadar360en2026-09-09T16:19:37.000ZAlpha Genesis backs biotech startups with $50M AGI Ventures fundhttps://www.pharmaradar360.com/article/eu-court-adviser-backs-challenge-to-pharmaceutical-wastewater-charges-f5177be301b558f1PharmaRadar360en2026-09-09T16:15:33.000ZEU court adviser backs challenge to pharmaceutical wastewater chargeshttps://www.pharmaradar360.com/article/kura-spins-diabetes-work-into-a-lilly-backed-biotech-startup-ee94fc840173114dPharmaRadar360en2026-09-09T16:14:40.000ZKura spins diabetes work into a Lilly-backed biotech startuphttps://www.pharmaradar360.com/article/biotech-stocks-to-consider-september-9th-b898d2190cfcaabbPharmaRadar360en2026-09-09T16:07:41.000ZBiotech Stocks To Consider - September 9thhttps://www.pharmaradar360.com/article/ima-group-to-showcase-all-in-one-solutions-at-cphi-milan-8f37948273925931PharmaRadar360en2026-09-09T16:06:08.000ZIMA Group to Showcase All-in-One Solutions at CPHI Milanhttps://www.pharmaradar360.com/article/faq-inside-the-latest-mfn-deals-signed-by-nine-drugmakers-03b08aa8809af0e0PharmaRadar360en2026-09-09T16:03:22.000ZFAQ: Inside the Latest MFN Deals Signed by Nine Drugmakershttps://www.pharmaradar360.com/article/one-state-s-abortion-ruling-could-affect-all-50-0b0a9758c1ef7862PharmaRadar360en2026-09-09T16:00:00.000ZOne state’s abortion ruling could affect all 50https://www.pharmaradar360.com/article/four-biotech-stories-heating-up-right-now-f51da81af50695d6PharmaRadar360en2026-09-09T15:55:26.000ZFour Biotech Stories Heating Up Right Nowhttps://www.pharmaradar360.com/article/fda-fills-four-senior-roles-including-top-officials-for-drugs-vaccines-and-tobac-12068fd76e56966cPharmaRadar360en2026-09-09T15:55:20.000ZFDA fills four senior roles, including top officials for drugs, vaccines and tobaccohttps://www.pharmaradar360.com/article/health-bill-promoting-visiting-impact-assessment-8e5c43f577238ed7PharmaRadar360en2026-09-09T15:46:27.000ZHealth Bill: promoting visiting - impact assessmenthttps://www.pharmaradar360.com/article/veraxa-biotech-designates-raju-willener-as-cfo-801ec29de9a56a5aPharmaRadar360en2026-09-09T15:46:25.000ZVERAXA Biotech Designates Raju Willener as CFOhttps://www.pharmaradar360.com/article/health-bill-medical-device-licensing-regime-impact-assessment-27313ede92bd836dPharmaRadar360en2026-09-09T15:46:24.000ZHealth Bill: medical device licensing regime - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-050bf26e4894b2caPharmaRadar360en2026-09-09T15:46:23.000ZHealth Billhttps://www.pharmaradar360.com/article/health-bill-mhra-reforms-impact-assessments-d4da977182c6d068PharmaRadar360en2026-09-09T15:46:20.000ZHealth Bill: MHRA reforms - impact assessmentshttps://www.pharmaradar360.com/article/health-bill-changes-to-pharmacy-appeals-process-impact-assessment-a5f9700a9414e0edPharmaRadar360en2026-09-09T15:46:16.000ZHealth Bill: changes to pharmacy appeals process - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-changes-to-section-75-of-nhs-act-2006-impact-assessment-5f9809bc31c7871fPharmaRadar360en2026-09-09T15:46:13.000ZHealth Bill: changes to section 75 of NHS Act 2006 - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-patient-safety-measures-impact-assessments-092abe2dadcce996PharmaRadar360en2026-09-09T15:46:09.000ZHealth Bill: patient safety measures - impact assessmentshttps://www.pharmaradar360.com/article/health-bill-role-and-functions-of-the-restructured-dhsc-fact-sheet-89c454d704f2bab3PharmaRadar360en2026-09-09T15:46:07.000ZHealth Bill: role and functions of the restructured DHSC - fact sheethttps://www.pharmaradar360.com/article/health-bill-structural-measures-to-icbs-and-foundation-trusts-impact-assessments-7a34cf0996abe91dPharmaRadar360en2026-09-09T15:46:06.000ZHealth Bill: structural measures to ICBs and foundation trusts - impact assessmentshttps://www.pharmaradar360.com/article/health-bill-providers-fact-sheet-ad8fa072da7a9f6ePharmaRadar360en2026-09-09T15:46:04.000ZHealth Bill: providers - fact sheethttps://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-fact-sheet-6de16d25a204e1efPharmaRadar360en2026-09-09T15:46:01.000ZHealth Bill: ICBs as strategic commissioners - fact sheethttps://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-impact-assessment-00de0de68dc58510PharmaRadar360en2026-09-09T15:45:59.000ZHealth Bill: abolishing NHS England - impact assessmenthttps://www.pharmaradar360.com/article/health-bill-icbs-as-strategic-commissioners-equality-impact-assessment-61dc9515198e3cd9PharmaRadar360en2026-09-09T15:45:54.000ZHealth Bill: ICBs as strategic commissioners - equality impact assessmenthttps://www.pharmaradar360.com/article/health-bill-impact-assessments-summary-744fa7c4f88e3806PharmaRadar360en2026-09-09T15:45:53.000ZHealth Bill: impact assessments summaryhttps://www.pharmaradar360.com/article/health-bill-abolishing-nhs-england-equality-impact-assessment-a15632314deab107PharmaRadar360en2026-09-09T15:45:46.000ZHealth Bill: abolishing NHS England - equality impact assessmenthttps://www.pharmaradar360.com/article/health-bill-equality-impact-assessments-summary-8eeb40343ce210f9PharmaRadar360en2026-09-09T15:45:40.000ZHealth Bill: equality impact assessments summaryhttps://www.pharmaradar360.com/article/wall-street-weighs-impact-on-dyn-stock-post-novartis-phase-3-failure-rbc-says-th-ab7d5395de69c328PharmaRadar360en2026-09-09T15:41:36.000ZWall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomeshttps://www.pharmaradar360.com/article/health-bill-promoting-visiting-equality-impact-assessment-33c1a8f7b32a87b9PharmaRadar360en2026-09-09T15:40:00.000ZHealth Bill: promoting visiting - equality impact assessmenthttps://www.pharmaradar360.com/article/health-bill-medicines-and-medical-devices-regulatory-reforms-fact-sheet-7269b5ea8e00e2dfPharmaRadar360en2026-09-09T15:40:00.000ZHealth Bill: medicines and medical devices regulatory reforms - fact sheethttps://www.pharmaradar360.com/article/novartis-s-del-desiran-misses-primary-endpoint-in-phase-3-dm1-trial-99ce4a179960b851PharmaRadar360en2026-09-09T15:31:11.000ZNovartis's Del-Desiran Misses Primary Endpoint in Phase 3 DM1 Trialhttps://www.pharmaradar360.com/article/why-the-biggest-ndc-12-risk-sits-in-the-handoffs-3d5e69a55011a8eaPharmaRadar360en2026-09-09T15:23:19.000ZWhy the Biggest NDC-12 Risk Sits in the Handoffshttps://www.pharmaradar360.com/article/decision-medical-devices-given-exceptional-use-authorisations-bea04f575ed28a14PharmaRadar360en2026-09-09T15:08:06.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/federal-appeals-court-hears-baseless-challenge-to-the-abortion-pill-mifepristone-940486b7c14cf63fPharmaRadar360en2026-09-09T14:56:47.000ZFederal Appeals Court Hears Baseless Challenge to the Abortion Pill Mifepristone — Againhttps://www.pharmaradar360.com/article/beeline-medicines-19dae1080a3df20cPharmaRadar360en2026-09-09T14:52:27.000ZBeeline Medicineshttps://www.pharmaradar360.com/article/this-biotech-stock-crashed-28-today-after-announcing-second-reverse-share-split-b0b395313df17574PharmaRadar360en2026-09-09T14:46:11.000ZThis Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Yearhttps://www.pharmaradar360.com/article/why-account-teams-call-claimguardrx-their-smartest-teammate-24ca28a696436c27PharmaRadar360en2026-09-09T14:24:19.000ZWhy Account Teams Call ClaimGuardRx Their Smartest Teammatehttps://www.pharmaradar360.com/article/the-proprietary-llm-behind-claimguardrx-s-detect-and-respond-engine-756b5ec033050dc5PharmaRadar360en2026-09-09T14:24:19.000ZThe Proprietary LLM Behind ClaimGuardRx's Detect-and-Respond Enginehttps://www.pharmaradar360.com/article/kura-creates-lilly-backed-spinout-armed-with-50m-to-advance-next-gen-diabetes-th-f97b4a180f77d74cPharmaRadar360en2026-09-09T14:20:14.000ZKura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyhttps://www.pharmaradar360.com/article/macrogenics-inexpensive-adc-tce-biotech-with-multiple-catalysts-ahead-nasdaq-mgn-3992c5961012659dPharmaRadar360en2026-09-09T14:15:35.000ZMacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead (NASDAQ:MGNX)https://www.pharmaradar360.com/article/ideaya-biosciences-doses-first-patient-in-phase-3-trial-d00198a17e0c725fPharmaRadar360en2026-09-09T14:10:00.000ZIDEAYA Biosciences Doses First Patient in Phase 3 Trialhttps://www.pharmaradar360.com/article/leerink-partners-initiates-coverage-on-teva-pharmaceutical-industries-nyse-teva-b4f76e98ec172cbdPharmaRadar360en2026-09-09T14:08:43.000ZLeerink Partners Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)https://www.pharmaradar360.com/article/the-transition-to-home-why-confidence-is-critical-to-patient-success-f53fe705f45b7442PharmaRadar360en2026-09-09T13:58:11.000ZThe Transition to Home: Why Confidence is Critical to Patient Successhttps://www.pharmaradar360.com/article/matica-bio-bondwell-partner-on-texas-biotech-d0f4351f2a06e4f3PharmaRadar360en2026-09-09T13:56:05.000ZMatica Bio, Bondwell Partner on Texas Biotechhttps://www.pharmaradar360.com/article/trump-order-directs-federal-push-on-psychedelic-drug-research-and-review-7a02808d8f427079PharmaRadar360en2026-09-09T13:48:15.000ZTrump Order Directs Federal Push on Psychedelic Drug Research and Reviewhttps://www.pharmaradar360.com/article/acrp-launches-2026-27-scholarship-and-grant-application-season-4a9b54371cfd920fPharmaRadar360en2026-09-09T13:45:52.000ZACRP Launches 2026–27 Scholarship and Grant Application Seasonhttps://www.pharmaradar360.com/article/orexin-discoverers-awarded-prestigious-lasker-award-0889c17faef35301PharmaRadar360en2026-09-09T13:43:39.000ZOrexin discoverers awarded prestigious Lasker awardhttps://www.pharmaradar360.com/article/luma-locks-down-15-year-410m-fund-for-life-science-investments-2229e6c1a7656df9PharmaRadar360en2026-09-09T13:43:05.000ZLuma locks down 15-year, $410M fund for life science investmentshttps://www.pharmaradar360.com/article/field-safety-notices-31-august-to-4-september-2026-4fbb5b1daae2c350PharmaRadar360en2026-09-09T13:41:45.000ZField Safety Notices: 31 August to 4 September 2026https://www.pharmaradar360.com/article/nutriband-ceo-gareth-sheridan-to-attend-inaugural-nasdaq-lab-biotech-summit-1307e17da858ae68PharmaRadar360en2026-09-09T13:31:00.000ZNutriband CEO Gareth Sheridan to Attend Inaugural Nasdaq LaB Biotech Summithttps://www.pharmaradar360.com/article/tyra-rolls-toward-pivotal-cancer-study-even-as-stock-deflates-06453e4e0f97fa39PharmaRadar360en2026-09-09T13:30:00.000ZTyra rolls toward pivotal cancer study even as stock deflateshttps://www.pharmaradar360.com/article/five-years-at-bio-mexico-gaining-ground-in-global-biotech-ec0a6f6068da0a75PharmaRadar360en2026-09-09T13:30:00.000ZFive Years at BIO: Mexico Gaining Ground in Global Biotechhttps://www.pharmaradar360.com/article/matica-biotechnology-and-bondwell-technologies-collaborate-to-advance-texas-biot-cf7873ac652d7f27PharmaRadar360en2026-09-09T13:09:29.000ZMatica Biotechnology and Bondwell Technologies Collaborate to Advance Texas Biotech Innovationhttps://www.pharmaradar360.com/article/guggenheim-reveals-top-biotech-stock-after-positive-clinical-trial-data-c106ca309e8a6793PharmaRadar360en2026-09-09T13:09:04.000ZGuggenheim Reveals Top Biotech Stock After Positive Clinical Trial Datahttps://www.pharmaradar360.com/article/ocugen-doses-first-patient-in-phase-3-ga-gene-therapy-trial-32970696c462f25bPharmaRadar360en2026-09-09T13:06:06.000ZOcugen doses first patient in phase 3 GA gene therapy trialhttps://www.pharmaradar360.com/article/decision-human-medicines-register-of-electronic-export-certificates-734f447a25d821dbPharmaRadar360en2026-09-09T13:03:01.000ZDecision: Human medicines: register of electronic export certificateshttps://www.pharmaradar360.com/article/viral-haemorrhagic-fever-acdp-algorithm-and-guidance-on-management-of-patients-a442005e4b179dafPharmaRadar360en2026-09-09T13:00:00.000ZViral haemorrhagic fever: ACDP algorithm and guidance on management of patientshttps://www.pharmaradar360.com/article/impact-biotech-announces-completion-of-treatment-in-phase-3-enlighted-trial-of-p-39acc0eee159b7fcPharmaRadar360en2026-09-09T13:00:00.000ZImPact Biotech Announces Completion of Treatment in Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC and Positive Regulatory Updateshttps://www.pharmaradar360.com/article/suddenly-this-summer-biotech-breaks-open-with-drug-approvals-ipos-will-it-last-25bef14c1bde5876PharmaRadar360en2026-09-09T12:57:00.000ZSuddenly this summer, biotech breaks open with drug approvals, IPOs. Will it last?https://www.pharmaradar360.com/article/decision-suspended-and-revoked-licences-and-registrations-for-manufacturers-and-258d162076f199f0PharmaRadar360en2026-09-09T12:42:29.000ZDecision: Suspended and revoked licences and registrations for manufacturers and wholesalers of medicines and ingredientshttps://www.pharmaradar360.com/article/nordic-biotech-ceos-reveal-secret-to-major-funding-and-pharma-deals-a3efea1f52140818PharmaRadar360en2026-09-09T12:37:57.000ZNordic biotech CEOs reveal secret to major funding and pharma dealshttps://www.pharmaradar360.com/article/don-t-ignore-the-insider-selling-in-biomarin-pharmaceutical-c392d2b0a526d595PharmaRadar360en2026-09-09T12:36:40.000ZDon't Ignore The Insider Selling In BioMarin Pharmaceuticalhttps://www.pharmaradar360.com/article/nitrosamines-from-detection-to-understanding-c0e645b8909bb3aaPharmaRadar360en2026-09-09T12:36:38.000ZNitrosamines: from detection to understandinghttps://www.pharmaradar360.com/article/anmat-dispuso-la-baja-de-habilitacion-de-la-firma-rehue-s-a-y-prohibio-sus-produ-95c8696ba780c6c0PharmaRadar360en2026-09-09T12:32:00.000ZANMAT dispuso la baja de habilitación de la firma REHUE S.A. y prohibió sus productos importadoshttps://www.pharmaradar360.com/article/pharmasource-podcast-how-exoz-is-running-a-10-cdmo-rfp-for-cdmo-selection-3a007b19e8cf1ab3PharmaRadar360en2026-09-09T12:31:32.000ZPharmaSource podcast: How EXOZ Is Running a 10-CDMO RFP for CDMO Selectionhttps://www.pharmaradar360.com/article/a-paid-pilot-will-test-trinity-biotech-cooling-fluids-in-ai-data-centers-7fd633709f73fc8cPharmaRadar360en2026-09-09T12:30:00.000ZA paid pilot will test Trinity Biotech cooling fluids in AI data centershttps://www.pharmaradar360.com/article/over-1-5-billion-to-help-nhs-withstand-year-round-pressure-cbf84c3935b064e9PharmaRadar360en2026-09-09T12:26:00.000ZOver £1.5 billion to help NHS withstand year-round pressurehttps://www.pharmaradar360.com/article/a-narcolepsy-drug-showed-median-reductions-of-up-to-88-8-in-sudden-muscle-loss-a-0ff7d04798652a97PharmaRadar360en2026-09-09T12:24:00.000ZA narcolepsy drug showed median reductions of up to 88.8% in sudden muscle-loss attacks.https://www.pharmaradar360.com/article/monthly-mandatory-surveillance-of-mrsa-mssa-gram-negative-bacteraemia-and-c-diff-35523ec4937619f8PharmaRadar360en2026-09-09T12:13:28.000ZMonthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2025 to August 2026https://www.pharmaradar360.com/article/atmospheric-nox-may-contribute-to-ndsri-formation-study-shows-717a069d3a62c417PharmaRadar360en2026-09-09T12:12:43.000ZAtmospheric NOₓ may contribute to NDSRI formation, study showshttps://www.pharmaradar360.com/article/novartis-back-to-back-phase-3-failures-for-pelacarsen-and-del-desiran-send-share-2bac2be2f578a969PharmaRadar360en2026-09-09T12:10:54.000ZNovartis: Back-to-Back Phase 3 Failures for Pelacarsen and Del-Desiran Send Shares Slidinghttps://www.pharmaradar360.com/article/world-health-expo-to-showcase-trillion-dollar-growth-across-pharma-biotech-longe-6803da287ace71b1PharmaRadar360en2026-09-09T12:07:00.000ZWorld Health Expo to showcase trillion-dollar growth across pharma, biotech, longevity and wellness at 2027 editionhttps://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-may-2e45bd7b86003737PharmaRadar360en2026-09-09T12:06:14.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, May 2026 to May 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-apri-b7f6f80136a72c29PharmaRadar360en2026-09-09T12:06:01.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, April 2026 to April 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-marc-a9688d88c3a30590PharmaRadar360en2026-09-09T12:05:44.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, March 2026 to March 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-febr-df1ca0002f7ddc6bPharmaRadar360en2026-09-09T12:05:28.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, February 2026 to February 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-june-a0324311fd4d4714PharmaRadar360en2026-09-09T12:05:12.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, June 2026 to June 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-july-e4a658a591d9a33ePharmaRadar360en2026-09-09T12:04:56.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, July 2026 to July 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-augu-e29136a0758c031fPharmaRadar360en2026-09-09T12:04:37.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, August 2026 to August 2027https://www.pharmaradar360.com/article/gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-monthly-data-sept-dd9b886471b7e27ePharmaRadar360en2026-09-09T12:04:22.000ZGram-negative, MRSA, MSSA bacteraemia and C. difficile infections: monthly data, September 2026 to September 2027